Skip to content
Search

Latest Stories

Letby case sparks PDA's call for regulating non-registered healthcare managers including in pharmacy practice

The life imprisonment sentence given to Nurse Lucy Letby, following her conviction for causing the deaths of seven newborns and attempting six more murders, has sparked crucial conversations about the enduring requirement for improved leadership, management, and transparency within the healthcare sector.

According to The Pharmacists’ Defence Association, the handling of the case demonstrates why lessons still need to be learned when clinical harm occurs, and questions are rightly being asked about the role and accountability of senior managers.


After the criminal case's conclusion and sentencing of Letby, the government ordered an inquiry to pinpoint system failures and suggest ways to prevent such tragedies in the future. While the outcomes of any forthcoming inquiry into the Letby case will require time, the PDA stated that various issues under scrutiny hold relevance across all healthcare domains including pharmacy.

The PDA noted that governments swiftly commission inquiries following prominent cases that expose operational and governance issues within NHS settings. However, they frequently hesitate to adopt the recommendations arising from these inquiries.

Despite many of the inquiries also highlighting the role of managers and senior leaders within the NHS settings where patient harm has occurred, the PDA noted that many aspects around the regulation of these managers have still not been accepted by government.

‘Unregulated pharmacy managers: A major concern’

In the realm of pharmacy practice, the PDA said it holds notable apprehensions about the influence of unregulated managers who wield power over registered pharmacists. This is particularly evident in community pharmacies, where the provision of NHS services is contracted to large private corporations, the union said.

While cases like Letby's have garnered national attention, the PDA noted that there are many less severe situations where patients are affected by the decisions of unregulated managers in positions of power.

The PDA consistently receives member reports about such occurrences including:

  • The request for a medicine that the pharmacist deems inappropriate and unsafe, which their non-pharmacist manager has overruled and sold.
  • The area manager who has demanded a pharmacist delivers a greater volume of vaccinations, despite the concerns raised by the pharmacist that the rest of the pharmacy operation could not be suitably supervised due to severe shortages of staff.
  • The temporary closure of pharmacies for purely commercial reasons depriving patients of access to vital medication.

While these incidents and numerous others might not capture national headlines, they still impact patients and undermine pharmacists' ability to uphold safety, the union added.

Drawing from its members' numerous experiences and in response to the Francis Inquiry report 2013, the PDA held a meeting with the General Pharmaceutical Council in 2015. During this meeting, the PDA advocated for the implementation of regulations for non-registered managers.

“Regrettably, this proposal was not approved,” PDA noted.

‘Duty of candour often neglected’

Responding to the GPhC's consultation on indicative sanctions in 2015, the PDA emphasised, "The Francis Report revealed that the duty of candour was often neglected. However, it also uncovered that healthcare staff's efforts to fulfil this duty could be hindered by the management and organisational culture of their employer."

“Without employer support, or at the very least, the guarantee of no internal disciplinary consequences for discussing errors or issues with patients/healthcare professionals, healthcare staff find it significantly harder to uphold the duty of candour. Consequently, focusing the guidance on sanctions against pharmacists without imposing any obligations on employers and non-pharmacists will result in an imbalanced and disproportionate regulatory approach,” the PDA said quoting the report.

‘Regulation is crucial’

A decade after the recommendations of the Francis Inquiry and 22 years following the suggestions of the Bristol Inquiry, the PDA emphasised that the current time undeniably demands a renewed dedication to enforcing regulations for non-registered healthcare managers at all sites where NHS services are delivered.

The union said the necessity of regulating individuals in management positions should not require another public inquiry or additional patient fatalities to be acknowledged. “This regulation is crucial to prevent the dismissal of raised concerns about individual actions, patient safety, and the potential for harm,” the PDA added.

Meanwhile, the PDA recently highlighted that wage theft is a common issue among pharmacists and trainee pharmacists, involving employers and contractors who often neglect to pay for overtime, make wage deductions, and withhold payments. In 2023, the union aided locum pharmacists in reclaiming £65,000 in unpaid wages. The PDA also emphasised the importance of pharmacists keeping their own copies of agreements and pointed out the range of employment and locum contracts.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less